Pharmaceutical Technology14d
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Lundbeck has gained ODD from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system atrophy (MSA).
Pharmabiz14d
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy
H. Lundbeck A/S (Lundbeck), a global pharmaceutical company, announced that the Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to its investigational ...
Yahoo Finance14d
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Lundbeck A/S. Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system atrophy (MSA). The designation ...
Taiwan News15d
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...
Medindia16d
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...